Seres Therapeutics (MCRB) Primary Endpoint Not Achieved in SER-109 Phase 2 ECOSPOR Study
Tweet Send to a Friend
Seres Therapeutics, Inc. (NASDAQ: MCRB) announced interim 8-week results from the ongoing SER-109 Phase 2 ECOSPORTM clinical study for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
